Latest Prostate-specific antigen Stories
Despite recommendations in 2008 from the United States Preventive Services Task Force against testing for prostate cancer in men aged 75 years or older, almost half of men in that age group continue to get screening tests.
An international research team led by Weill Cornell Medical College investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer.
Do you or someone you know suffer from advanced prostate cancer (CRPC)? A new treatment may be available that can help treat the deadly disease.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.
Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug.
Prostate cancer is the most common cause of death from cancer in men over age 75. An 11 year study looked at death in men whom prostate cancer was diagnosed pre death and post death.